"Liver Cirrhosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Descriptor ID |
D008103
|
| MeSH Number(s) |
C06.552.630
|
| Concept/Terms |
Liver Cirrhosis- Liver Cirrhosis
- Cirrhosis, Liver
- Cirrhoses, Liver
- Liver Cirrhoses
- Hepatic Cirrhosis
- Cirrhoses, Hepatic
- Cirrhosis, Hepatic
- Hepatic Cirrhoses
|
Below are MeSH descriptors whose meaning is more general than "Liver Cirrhosis".
Below are MeSH descriptors whose meaning is more specific than "Liver Cirrhosis".
This graph shows the total number of publications written about "Liver Cirrhosis" by people in this website by year, and whether "Liver Cirrhosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 2 | 4 |
| 1998 | 5 | 0 | 5 |
| 1999 | 2 | 0 | 2 |
| 2000 | 3 | 2 | 5 |
| 2001 | 5 | 3 | 8 |
| 2002 | 4 | 2 | 6 |
| 2003 | 7 | 3 | 10 |
| 2004 | 8 | 5 | 13 |
| 2005 | 8 | 5 | 13 |
| 2006 | 8 | 3 | 11 |
| 2007 | 5 | 3 | 8 |
| 2008 | 9 | 5 | 14 |
| 2009 | 8 | 2 | 10 |
| 2010 | 12 | 4 | 16 |
| 2011 | 13 | 11 | 24 |
| 2012 | 16 | 4 | 20 |
| 2013 | 20 | 2 | 22 |
| 2014 | 18 | 4 | 22 |
| 2015 | 17 | 9 | 26 |
| 2016 | 22 | 7 | 29 |
| 2017 | 25 | 10 | 35 |
| 2018 | 22 | 11 | 33 |
| 2019 | 25 | 6 | 31 |
| 2020 | 26 | 13 | 39 |
| 2021 | 17 | 30 | 47 |
| 2022 | 5 | 37 | 42 |
| 2023 | 6 | 47 | 53 |
| 2024 | 21 | 9 | 30 |
To return to the timeline,
click here.
Below are the most recent publications written about "Liver Cirrhosis" by people in Profiles.
-
Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial. Gut. 2024 Nov 11; 73(12):2037-2044.
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
-
National Liver Cancer Screening Trial (TRACER) study protocol. Hepatol Commun. 2024 Nov 01; 8(11).
-
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
-
Comparing imaging modalities in the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease. J Pediatr Gastroenterol Nutr. 2024 Dec; 79(6):1192-1198.
-
Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism. Gut Microbes. 2024 Jan-Dec; 16(1):2399260.
-
Perioperative outcomes after hepatectomy for hepatocellular carcinoma among patients with cirrhosis, fatty liver disease, and clinically normal livers. Surg Oncol. 2024 Oct; 56:102114.
-
Impact of acute kidney injury response on survival and liver transplant rates in hospitalized patients with cirrhosis awaiting liver transplantation: Results from the HRS-HARMONY consortium. Liver Transpl. 2024 Nov 01; 30(11):1106-1115.
-
Cystatin C and the difference between cystatin C and serum creatinine: Improved metrics to predict waitlist mortality among patients with decompensated cirrhosis. Liver Transpl. 2025 Jan 01; 31(1):24-31.
-
Medication burden and anticholinergic use are associated with overt HE in individuals with cirrhosis. Hepatol Commun. 2024 08 01; 8(8).